Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2018 May;130:73-89. doi: 10.1016/j.addr.2018.07.011. Epub 2018 Jul 27.

Harnessing albumin as a carrier for cancer therapies.

Author information

1
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN.
2
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN. Electronic address: craig.duvall@vanderbilt.edu.

Abstract

Serum albumin, a natural ligand carrier that is highly concentrated and long-circulating in the blood, has shown remarkable promise as a carrier for anti-cancer agents. Albumin is able to prolong the circulation half-life of otherwise rapidly cleared drugs and, importantly, promote their accumulation within tumors. The applications for using albumin as a cancer drug carrier are broad and include both traditional cancer chemotherapeutics and new classes of biologics. Strategies for leveraging albumin for drug delivery can be classified broadly into exogenous and in situ binding formulations that utilize covalent attachment, non-covalent association, or encapsulation in albumin-based nanoparticles. These methods have shown remarkable preclinical and clinical successes that are examined in this review.

KEYWORDS:

Albumin; Cancer; Drug carrier; Drug conjugate; Drug delivery; Prodrug

PMID:
30012492
PMCID:
PMC6200408
[Available on 2019-07-27]
DOI:
10.1016/j.addr.2018.07.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center